drugset / Trial / NCT05818982
To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II study to evaluate the effectiveness and safety of Afininib compared to irinotecan in the 3-gene RNA sequencing (ALTRK) negative advanced esophageal squamous squamous carcinoma.
Timeline
- Start
- 2023-02-09
- Primary completion
- 2025-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Comparator | Irinotecan | Small molecule | 140 mg/m2 | Intravenous |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |